ReviewDigestive diseases and sciences2026
Breaking the Calcium Overload Cycle in Acute Pancreatitis: Emerging Pharmacological Strategies.
Review in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyze current experimental and clinical studies regarding the role of calcium dysregulation in the pathogenesis of AP and to evaluate the efficacy of various pharmacological approaches to its correction.
methodsA literature review was conducted using PubMed, Scopus, and Google Scholar databases up to October 2025. Included were in vitro, in vivo, and clinical studies addressing the mechanisms of calcium imbalance in AP and the effects of different pharmacological agents targeting calcium regulation.
resultsKey molecular targets for calcium-targeted therapy were identified, including IP3 and ryanodine receptors, SOC/CRAC channels, TMEM16A, the PI3K/Akt pathway, and the calcineurin/NFAT signaling cascade. Therapeutic compounds such as caffeine, dantrolene, docosahexaenoic acid (DHA), Orai1 channel inhibitors (CM4620/Auxora, GSK-7975A), TMEM16A inhibitors, insulin, calcium chelators (BAPTA-AM), calcineurin inhibitors (cyclosporin A, tacrolimus), and microRNAs (e.g., miR-26a) demonstrated the ability to reduce cytosolic calcium overload, suppress zymogen activation, stabilize mitochondrial function, and attenuate inflammation. Some of these agents are already used in other medical fields or are undergoing clinical trials as candidate treatments for AP.
conclusionsPharmacological modulation of calcium homeostasis represents a promising pathogenetic approach to the treatment of acute pancreatitis. Existing evidence supports the need for further multicenter clinical studies to confirm the safety and efficacy of calcium-targeted strategies in routine clinical practice.
Indexed as
Identifiers
41703270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.